Xultophy is a single, once-daily injection that combines Tresiba — an insulin degludec injection — and Victoza — a liraglutide injection. The drug, intended to help adults with type 2 diabetes achieve better glycemic control, represents a new class of diabetes treatments.
Novo Nordisk plans to launch Xultophy in the first half of 2017. The drugmaker said it would “work diligently” to ensure the drug is covered on health plans nationwide and will also offer a savings card to help patients lower insurance co-pays, according to a news release.
More articles on supply chain:
DHL Express will invest $185M in US operations to support increased shipping volumes: 3 takeaways
Gartner names top 25 supply chains in healthcare
6 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.